The first generic version of Biogen’s (Nasdaq: BIIB) main multiple sclerosis therapy, Tecfidera (dimethyl fumarate), is to launch in the USA.
Developed by Netherlands-incorporated generics firm Mylan (Nasdaq: MYL), the copycat drug has been subjected to intense legal efforts aimed at preventing the alternative from entering the market.
But after a string of legal defeats, Mylan won a District Court judgment in June, paving the way for launch many years earlier than would otherwise have been possible.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze